GILEAD SCIENCES, INC. — Director's Dealing 2018

Apr 27, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2018-04-23

Reporting Person: McHutchison John G (Chief Scientific Off/HeadR&D)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	22906	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-qualified Stock Option (Right to Buy)	$16.89	2020-07-22	Common Stock (19950)		Direct
Non-qualified Stock Option (Right to Buy)	$24.295	2022-01-26	Common Stock (16850)		Direct
Non-qualified Stock Option (Right to Buy)	$40.56	2023-02-01	Common Stock (29710)		Direct
Non-qualified Stock Option (Right to Buy)	$80.65	2024-02-01	Common Stock (42290)		Direct
Non-qualified Stock Option (Right to Buy)	$104.83	2025-02-01	Common Stock (51690)		Direct
Non-qualified Stock Option (Right to Buy)	$84.05	2026-02-01	Common Stock (58950)		Direct
Non-qualified Stock Option (Right to Buy)	$72.25	2027-02-02	Common Stock (63590)		Direct
Non-qualified Stock Option (Right to Buy)	$83.49	2028-02-01	Common Stock (62910)		Direct
Restricted Stock Unit	$		Common Stock (2930)		Direct

Footnotes

F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.

F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F4: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.